Neo-Candimyk® (Itraconazole)

Itraconazole, the active ingredient in Neo-Candimyk®, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of systemic fungal infections in adults and children as prescribed.

GNH USA supplies Neo-Candimyk® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neo-Candimyk® (itraconazole) is used to manage invasive fungal infections across several disease families. - Candidiasis: effective for systemic and invasive Candida infections. - Aspergillosis: treats chronic and invasive forms of Aspergillus infection. - Blastomycosis: used for severe Blastomyces dermatitidis infections. - Histoplasmosis: indicated for disseminated Histoplasma capsulatum disease. - Systemic mycoses: provides therapy for a broad spectrum of deep‑tissue fungal infections.

Adverse reactions may occur with itraconazole therapy and are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes of emesis. - Abdominal pain: discomfort or cramping in the stomach area. - Headache: transient mild to moderate headache. - Rash: skin redness or itching. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of pre‑existing heart conditions. - Severe hypotension: marked drop in blood pressure. - Visual disturbances: blurred vision or photophobia. - Anaphylaxis: rare but life‑threatening allergic reaction.

Before initiating therapy, clinicians should consider several safety measures. - Liver monitoring: assess baseline liver function and repeat periodically. - Cardiac assessment: use caution in patients with heart failure. - Drug interaction review: evaluate concomitant medications for potential interactions. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Dose adjustment: modify dosing in patients with hepatic impairment. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Itraconazole has a notable potential for pharmacokinetic interactions.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing itraconazole exposure. - Carbamazepine: strong enzyme inducer, markedly lowers drug levels. - St. John’s wort: herbal inducer that decreases efficacy. - Ketoconazole: competitive inhibition may increase toxicity. - HIV protease inhibitors (e.g., ritonavir): can cause dangerous plasma level spikes.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Phenytoin: can lower itraconazole concentrations. - Macrolide antibiotics (e.g., erythromycin): may increase levels. - Calcium channel blockers (e.g., verapamil): may raise plasma concentrations. - Oral contraceptives: efficacy may be reduced, advise alternative contraception.